Halozyme adds James Daly to board of directors
Halozyme Therapeutics disclosed the September 28, 2026 election in an 8-K filed with the SEC.
SEC filing
Latest
7 stories
Yesterday
Tuesday, September 22
Halozyme completes $1.5 billion convertible notes offering due 2033
The company plans to use part of the proceeds to fund capped calls and buy back existing 2027 and 2028 convertible notes.
SEC filing
Friday, September 18
Halozyme prices upsized $1.3 billion convertible notes offering due 2033
The company raised the deal from an original $1.05 billion and gave initial purchasers an option for $200 million more, with proceeds set to fund capped calls and repurchase older notes.
SEC filing
Thursday, August 27
BMS registers new deucravacitinib continuation study; prior week's trial results still stand
Tuesday, August 18
Halozyme adds Dannielle Appelhans to board of directors
Halozyme Therapeutics disclosed the August 14, 2026 board appointment in an 8-K filed with the SEC.
SEC filing
Friday, August 7
Roche results post for two terminated Morpheus umbrella trials; new Phase 1/2 studies registered
Thursday, August 6
Halozyme posts record Q2 2026, raises full-year guidance on royalty growth
Five new ENHANZE and Hypercon collaborations signed through July, including deals with Vertex, GSK, Incyte and Oruka, push revenue and EBITDA guidance higher.
SEC filing